INKT — MiNK Therapeutics, Inc.

INKT Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Cash and cash equivalents at the end of Q1 2026: approximately $9.5 million, down from $13.4 million at the end of 2025.
• Net loss for Q1 2026: approximately $2.7 million ($0.57 per share), compared to a loss of $2.8 million ($0.70 per share) in Q1 2025.
• The company raised approximately $3 million through an aftermarket sales agreement during the quarter.
• Cash runway is expected to last for at least the next 12 months, supporting ongoing clinical trials.

2. Strategic Updates and Business Highlights:

• INKT has presented data at four major scientific meetings, highlighting progress in their invariant natural killer T cell technology (agenT-797) for various conditions, including refractory gastric cancer and severe lung injury.
• A new collaboration was announced with a partner to advance targeted TCR engineered iNKT cell therapy for pediatric cancers, emphasizing the off-the-shelf nature of their therapies.
• A randomized Phase II clinical trial for agenT-797 in patients with severe acute lung injury and ARDS has been initiated, with plans for seamless transition to Phase III based on early results.
• The company is focusing on operational efficiency and capital discipline, leveraging partnerships and established clinical infrastructures, particularly in Ukraine.

3. Forward Guidance and Outlook:

• Preliminary data from the randomized Phase II trial is expected in the second half of 2026, with endpoints including overall survival and ventilator-free days.
• The company is preparing for potential regulatory interactions with the FDA regarding trial designs and development plans.
• Continued focus on expanding the applicability of their iNKT cell technology across various disease settings, including cancer and severe inflammatory conditions.

4. Bad News, Challenges, or Points of Concern:

• The decline in cash reserves raises concerns about financial sustainability and the ability to fund operations without additional financing.
• The competitive landscape in cell therapy remains challenging, with ongoing pressures from other therapies and companies in the same space.
• The complexity of developing therapies for critical conditions like ARDS poses significant operational and regulatory hurdles, which could impact timelines and outcomes.

5. Notable Q&A Insights:

• The randomized Phase II trial will enroll 90 patients, with a 1:1 randomization between treatment and placebo groups.
• There is potential for identifying biomarkers that could predict patient response to therapy, which may accelerate development timelines.
• The company is exploring commercial strategies and distribution models, particularly in light of the significant healthcare costs associated with ARDS and respiratory distress.
• Insights from the Q&A highlighted the adaptability of iNKT cells in different disease environments, suggesting a promising avenue for future research and therapeutic applications.

Overall, INKT is making significant strides in its clinical programs and partnerships, although financial pressures and competitive challenges remain key areas of focus.